Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention
Authors:
- Paul W. ArmstrongPAPaul W. Armstrong
- Peter X. AdamsPAPeter X. Adams
- Hussein R. Al-KhalidiHAHussein R. Al-Khalidi
- Christian HammCHChristian Hamm
- David HolmesDHDavid Holmes
- William O'NEillWOWilliam O'NEill
- Thomas G. TodaroTTThomas G. Todaro
- Alec VahanianAVAlec Vahanian
- Frans Van de WerfFWFrans Van de Werf
- Christopher B. GrangerCGChristopher B. Granger
- 1 March 2005
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 149 (3) , 402-407
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive SummaryCirculation, 2004
- Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary BypassJAMA, 2004
- Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial InfarctionCirculation, 2003
- The inflammatory response in myocardial infarctionCardiovascular Research, 2002
- Myocardial Infarction and Apoptosis After Myocardial Ischemia and ReperfusionCirculation, 1998
- Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.Journal of Clinical Investigation, 1995
- Does reperfusion injury exist in humans?JACC, 1993
- Mechanism of myocardial "stunning".Circulation, 1990
- Discrete Sequential Boundaries for Clinical TrialsBiometrika, 1983
- Repeated Significance Testing for a General Class of Statistics Used in Censored Survival AnalysisJournal of the American Statistical Association, 1982